Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Insider Terrie Curran Sells 16,851 Shares

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) insider Terrie Curran sold 16,851 shares of the firm’s stock in a transaction that occurred on Friday, March 22nd. The stock was sold at an average price of $9.11, for a total transaction of $153,512.61. Following the sale, the insider now directly owns 410,784 shares of the company’s stock, valued at approximately $3,742,242.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Phathom Pharmaceuticals Stock Performance

NASDAQ PHAT opened at $10.62 on Friday. The company has a 50 day moving average of $8.50 and a 200-day moving average of $8.85. The company has a quick ratio of 10.22, a current ratio of 10.25 and a debt-to-equity ratio of 5.56. Phathom Pharmaceuticals, Inc. has a 1-year low of $6.07 and a 1-year high of $17.02.

Phathom Pharmaceuticals (NASDAQ:PHAT) last issued its quarterly earnings results on Thursday, March 7th. The company reported ($0.80) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.12. The company had revenue of $0.68 million during the quarter, compared to analyst estimates of $0.93 million. During the same period in the prior year, the business earned ($1.33) EPS. As a group, analysts expect that Phathom Pharmaceuticals, Inc. will post -4.22 earnings per share for the current year.

Institutional Trading of Phathom Pharmaceuticals

A number of institutional investors have recently bought and sold shares of PHAT. Swiss National Bank grew its holdings in Phathom Pharmaceuticals by 7.7% during the 1st quarter. Swiss National Bank now owns 33,400 shares of the company’s stock worth $455,000 after acquiring an additional 2,400 shares during the period. JPMorgan Chase & Co. grew its holdings in Phathom Pharmaceuticals by 1.7% during the 1st quarter. JPMorgan Chase & Co. now owns 175,562 shares of the company’s stock worth $2,389,000 after acquiring an additional 3,001 shares during the period. Bank of New York Mellon Corp grew its holdings in Phathom Pharmaceuticals by 3.3% during the 1st quarter. Bank of New York Mellon Corp now owns 61,288 shares of the company’s stock worth $834,000 after acquiring an additional 1,948 shares during the period. MetLife Investment Management LLC grew its holdings in Phathom Pharmaceuticals by 58.5% during the 1st quarter. MetLife Investment Management LLC now owns 12,302 shares of the company’s stock worth $167,000 after acquiring an additional 4,540 shares during the period. Finally, Rhumbline Advisers grew its holdings in Phathom Pharmaceuticals by 16.0% during the 1st quarter. Rhumbline Advisers now owns 19,968 shares of the company’s stock worth $272,000 after acquiring an additional 2,761 shares during the period. Institutional investors and hedge funds own 99.01% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $26.00 price objective on shares of Phathom Pharmaceuticals in a report on Friday, March 22nd.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.